Date: 2016-11-23
Type of information: Production agreement
Compound: interferon alpha
Company: Neovacs (France) 3P Biopharmaceuticals (Spain)
Therapeutic area: Technology - Services
Type agreement: manufacturing production
Action mechanism:
Disease:
Details: * On November 23, 2016, Neovacs announced a partnership with 3P Biopharmaceuticals, a leader in the production of biological drugs, for the manufacture of interferon alpha. This collaboration follows the recent acquisition of the technology for the manufacture of IFNalpha by Neovacs from Amegabiotech. This license agreement will allow Neovacs to directly transfer Amegabiotech's technology to the production site of 3P Biopharmaceuticals, which will ensure the manufacture of the IFNalpha cytokine. Neovacs has now secured the complete production chain for the manufacture of interferon alpha. This agreement complements the partnership signed with Stellar Biotechnologies, the supplier of the other main component of IFNalpha Kinoid, Keyhole Limpet Hemocyanin (KLH).
Financial terms:
Latest news:
